GlassScriptPhysician profile
Ryan C Myers
NPI 1942700182
$4,889.96
in general payments reported to CMS, 2019-2025
21 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $736 · 2022: $862 · 2023: $725 · 2024: $1,148 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.11 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,127.12 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $807.79 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $618.75 | 2021-2024 | Rexulti |
| Alkermes, INC. | $350.81 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $277.90 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $266.63 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $248.95 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $183.73 | 2021-2025 | Trintellix |
| Corium, LLC | $133.17 | 2024-2025 | Azstarys |
| Almatica Pharma LLC | $132.30 | 2022-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $105.26 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $102.20 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $101.77 | 2025 | Fanapt |
| Tris Pharma INC | $94.14 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Noven Therapeutics, LLC | $67.15 | 2022-2025 | Xelstrym, Secuado |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $66.34 | 2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $65.84 | 2021-2022 | |
| Lundbeck LLC | $42.99 | 2021 | |
| Ironshore Pharmaceuticals INC. | $42.56 | 2024 | |
| Collegium Pharmaceutical, INC. | $39.62 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.